Head-to-head evidence
GSK3862995 vs itepekimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: IL-33 · full Chronic Obstructive Pulmonary Disease pipeline
GSK3862995
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06154837 (registry estimate)
itepekimab
Developed by Sanofi and partners
NCT04751487 · Phase 3 · completed
This was a large, randomized, quadruple-masked, placebo-controlled trial with a clinical primary endpoint: the annualized rate of moderate or severe COPD exacerbations. Because the registry has not posted the primary comparison results, it is not possible to determine whether the endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GSK3862995's landscape · itepekimab's landscape